Adcendo reports 30% response rate for soft tissue sarcoma ADC

Adcendo has reported a 30% objective response rate for its experimental antibody-drug conjugate ADCE-D01 in a Phase 1/2 trial involving patients with advanced soft tissue sarcoma.

The initial clinical data also showed an 85% disease control rate, with all observed responses ongoing at the data cut-off.

The findings come from the ADCElerate1 study, which is evaluating ADCE-D01 in patients with metastatic or unresectable soft tissue sarcoma (STS) who have previously received systemic treatment.

Of the 27 response-evaluable patients receiving treatment every two weeks, eight experienced a partial response, giving an objective response rate of 30%. Five responses were confirmed, while three remain unconfirmed.

Disease control was achieved in 23 of the 27 patients (85%). Median follow-up was 3.4 months, and median duration of response had not yet been reached. At the data cut-off, 81% of patients remained on treatment.

Responses observed across different sarcoma subtypes

The 27 patients represented 12 different STS subtypes, suggesting potential activity across a range of these heterogeneous cancers.

The trial enrolled 47 adults with advanced STS, including 17 different subtypes. Participants had received a median of two previous lines of systemic treatment, including chemotherapy and targeted therapies.

Patrick Schöffski, head of the department of general medical oncology at University Hospitals Leuven and principal investigator of ADCElerate1, said: “Advanced soft tissue sarcoma remains one of our most challenging clinical areas, where historic second-line options routinely yield response rates of only 4 – 10%. The observed 30% objective response rate and high disease control rate seen with ADCE-D01 could mark an important shift, offering a desperately needed novel therapy across STS subtypes for patients who have exhausted standard therapies.”

The results were presented in a late-breaking oral presentation at the 2026 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona.

Two-week dosing schedule shows manageable safety

The study initially evaluated weekly administration of ADCE-D01 in 18 patients at doses ranging from 0.5 to 3.4 mg/kg. Investigators subsequently moved to a two-week dosing schedule based on the pharmacokinetic findings from the weekly regimen.

The next 29 patients received doses ranging from 3.4 to 5.5 mg/kg every two weeks.

The most common treatment-related side effects with the two-week schedule were nausea (59%), infusion-related reactions (41%), tiredness (38%) and hair loss (35%). Neutropenia was the most common haematological side effect, affecting 31% of patients.

Side effects resulted in dose reductions in 10% of patients on the two-week schedule, but no patients discontinued treatment because of them.

Prophylactic granulocyte colony-stimulating factor (G-CSF) was also associated with a lower incidence of severe neutropenia. Grade 3 or higher neutropenia occurred in 14% of patients receiving G-CSF, compared with 43% of those who did not receive prophylactic treatment.

The maximum tolerated dose for the two-week regimen has not yet been reached. No cases of interstitial lung disease, febrile neutropenia or stomatitis were reported.

Adcendo continues recruitment

ADCE-D01 is an antibody-drug conjugate targeting uPARAP, an endocytic receptor expressed in several cancers of mesenchymal origin, including soft tissue sarcoma, osteosarcoma, gastrointestinal stromal tumours, mesothelioma and glioblastoma.

The candidate combines an antibody targeting uPARAP with a protease-cleavable linker and deruxtecan payload. The approach is designed to deliver the cytotoxic drug into cancer cells following receptor internalisation.

Lone H Ottesen, chief medical officer at Adcendo, said: “We are extremely pleased to share the first clinical data for ADCE-D01 at ENA which demonstrate encouraging antitumor activity and disease control across multiple STS subtypes in a population with substantial unmet medical need. We believe these data point to ADCE-D01’s transformative treatment potential, while also validating Adcendo’s target biology and indication-driven approach to developing a pipeline of highly effective and well tolerated ADCs. Together with world leading sarcoma centers in the US and Europe, we continue to enroll patients in the ADCElerate1 study as we work to further explore ADCE-D01’s potential and define the development path.”

ADCE-D01 has received Fast Track and Orphan Drug Designation from the US Food and Drug Administration for the treatment of soft tissue sarcoma. Recruitment in the Phase 1/2 ADCElerate1 trial is continuing in the US and Europe.

Mail Icon

news via inbox

Sign up for our newsletter and get the latest news right in your inbox